Overall, sirolimus therapy was demonstrated to stabilize lung function, improve quality of life, reduce the size of chylothorax, decrease the volume of renal AMLs, and decrease serum VEGF-D level16–23. The gene discussed is VEGFD; the disease is Chylothorax.